MECP2 disorders: from the clinic to mice and back

Laura Marie Lombardi,1,2,3 Steven Andrew Baker,2,4,5 and Huda Yahya Zoghbi1,2,3,4

1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. 2Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, Texas, USA. 3Howard Hughes Medical Institute, 4Program in Developmental Biology, and 5Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA.

Two severe, progressive neurological disorders characterized by intellectual disability, autism, and developmental regression, Rett syndrome and MECP2 duplication syndrome, result from loss and gain of function, respectively, of the same critical gene, methyl-CpG-binding protein 2 (MECP2). Neurons acutely require the appropriate dose of MECP2 to function properly but do not die in its absence or overexpression. Instead, neuronal dysfunction can be reversed in a Rett syndrome mouse model if MeCP2 function is restored. Thus, MECP2 disorders provide a unique window into the delicate balance of neuronal health, the power of mouse models, and the importance of chromatin regulation in mature neurons. In this Review, we will discuss the clinical profiles of MECP2 disorders, the knowledge acquired from mouse models of the syndromes, and how that knowledge is informing current and future clinical studies.

Introduction
Austrian pediatrician Andreas Rett first reported in 1966 on young females exhibiting progressive dementia, motor loss, and stereotyped hand movements following normal development in their first 1 to 1.5 years of life (1). He filmed their unique clinical presentation, attempting to raise awareness and find similar cases of what he termed “cerebral atrophy with hyperammonemia.” Unfortunately, increased awareness of the condition occurred slowly due to the relative rarity of the condition, the fact that Dr. Rett published almost exclusively in German, and an equipment error resulting in only apparent hyperammonemia. It was not until 1983, when Swedish neurologist Bengt Hagberg and colleagues synthesized a series of similar cases from Europe in the Annals of Neurology, that the striking regression syndrome would truly enter the international medical consciousness (2). In honor of the original observer and the continued dedication of Dr. Andreas Rett to these patients, the disorder would henceforth be known as Rett syndrome.

In the years that followed, a clear clinical picture began to crystallize. Rett syndrome occurs in 1 in 10,000 live female births and is sporadic in over 99% of the cases (3). What genetic or environmental insult could result in such an acute defect around the peak of infant synaptogenesis? In 1999, Dr. Ruthie Amir, a postdoctoral fellow, discovered that loss-of-function mutations in methyl-CpG-binding protein 2 (MECP2) formed the genetic basis of Rett syndrome (4). Less than 6 years later, duplication of the very same gene was implicated in a severe male intellectual disability syndrome associated with premature death, MECP2 duplication syndrome (MDS) (5). In this Review, we will discuss the clinical consequences of MECP2 loss and gain of function, the power and significance of mouse models of these disorders, our molecular knowledge of MeCP2, and the path these models and molecular knowledge have paved for clinical trials.

Manifestations of disease
MECP2 dosage sensitivity. In their landmark 1983 article, Hagberg and colleagues catalogued 35 patients encountered over the course of 21 years in three different European countries (2). This breadth of clinical experience enabled them to propose four distinct phases of Rett syndrome: (a) stagnation of development after 7 to 18 months, (b) rapid deterioration, (c) a pseudostationary phase, and (d) late motor deterioration (6). Developmental stagnation is typified by a failure to meet major developmental milestones, including word development, social interaction, and motor ability. This developmental stagnation is further evidenced by acquired microcephaly and overall growth delay. Rapid deterioration results in loss of previously acquired abilities, such as walking or pulling to a stand, word use or babbling, affinity for or attention to social interaction, and grasping or gesturing. Purposeful hand movements are replaced by stereotypies, such as hand clapping and wringing. Respiratory abnormalities, such as hyperventilation and apneas, also often emerge at this stage. Mental decline coincides with motor dysfunction characterized by apraxia and often an ataxic gait. In the so-called pseudostationary phase (onset at ~3 to 10 years of age), seizures and scoliosis are common, but social interaction defects subside somewhat. Eventually, many patients lose the ability to ambulate and sometimes develop parkinsonian features in the phase of late motor deterioration (7, 8). These clinical features occur in the absence of any evidence of neuronal degeneration but are accompanied by decreased brain size, most likely resulting from the smaller neurons and reduced dendritic branching (9).

The apparent gender specificity of this disorder was just as puzzling as the clinical presentation of regression. To explain this “exclusive involvement of females,” Hagberg proposed early on that Rett syndrome was due to a dominant X-linked mutation that resulted in nonviable hemizygous males (2). Further, he argued that his model predicted the rare occurrence of Klinefelter males (XXY) with Rett symptoms. Indeed, such a male was identified in 1999 (10). Although 99% of Rett cases are sporadic, the genetic basis of the disorder was affirmed by multiple examples of identical twin sisters concordant for Rett syndrome (11, 12). In the
handful of familial examples, skewed X chromosome inactivation (XCI) was observed in asymptomatic mothers but not in the affected daughters, suggesting that carrier mothers preferentially inactivated the mutant allele in the majority of cells (13–15). Determining the causative gene on the X chromosome relied on painstaking exclusion mapping of rare familial cases (16). Once the candidate region was narrowed down, sequencing of candidate genes in sporadic cases revealed mutations in MECP2 (4). Indeed, more than 95% of patients diagnosed with typical Rett syndrome have mutations in MECP2 (17).

Knowing the causative gene on the X chromosome clarified the striking female bias of the disorder. First, genotyping revealed MECP2 mutations in more than 95% of patients diagnosed with typical Rett syndrome have mutations in MECP2 (17).

Mouse models of loss and gain. After establishing that loss-of-function mutations in MECP2 cause Rett syndrome, two Mecp2-null mouse models were successfully generated in 2001 (43, 44). Female mice heterozygous for the null allele are initially normal but slowly develop a stiff, uncoordinated gait, breathing difficulties, and hindlimb clasping; they are hypoactive starting at about 16 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age (43, 44).

It has been determined that common minimal duplicated region includes only MECP2 and the adjacent gene IRAKI (34–36). Males with MDS exhibit infantile hypotonia, autistic features, gait abnormalities, seizures, and recurrent infections (5, 36–39). The inclusion of IRAKI, which encodes IL receptor–associated kinase 1, in the duplicated region was hypothesized to mediate the immunological defects of the patients; however, recent work indicates that overexpression of MECP2 is sufficient to impair T cell function (40). Though approximately 40% of MDS males die before the age of 25 (41), again, females are more protected due to the presence of a WT X chromosome. Unlike Rett syndrome, this disorder is largely familial, as female carriers are healthy enough to transmit the allele. However, the health of female carriers appears to correspond to the extent of favorable XCI. Female carriers with 85% or more cells expressing the WT X chromosome exhibit anxiety and depression (38) but do not exhibit intellectual disability (5), whereas carriers with less favorable skewing exhibit mild intellectual disability and Rett-like phenotypes (42).

Mouse models of loss and gain. After establishing that loss-of-function mutations in MECP2 cause Rett syndrome, two Mecp2-null mouse models were successfully generated in 2001 (43, 44). Female mice heterozygous for the null allele are initially normal but slowly develop a stiff, uncoordinated gait, breathing difficulties, and hindlimb clasping; they are hypoactive starting at about 16 weeks of age (43, 44). Hemizygous males exhibit a similar but more rapid regression, with approximately 50% dying by 8 to 11 weeks of age. Similar to the neuroanatomical findings in humans, murine Rett models also display microcephaly, without gross neuropathological changes or neurodegeneration. Specifically, mouse and human neurons without MeCP2 have smaller somas (43, 45, 46) and decreased dendritic complexity (47–51). A decrease in synaptic plasticity, or the ability of neurons to change their synaptic strength in response to activity, is also observed in many neuronal types (52–54). Abnormalities in neurotransmitter concentrations occur in KO mice (55–59) as well as in patients with Rett syndrome (60–62). Thus, the major human phenotypes of Rett syndrome are recapitulated in mice, allowing for functional disease dissection in this model system (Table 1).

Although Mecp2 is broadly expressed, animals with the null mutation only in the CNS were indistinguishable from those with the mutation throughout the body (43, 44). This strongly indicated that the exhibited movement and breathing defects stemmed from loss of Mecp2 specifically in the CNS. Further, the notion...
that MeCP2 is required for general neuronal health is underscored by the dysfunction associated with the many different neuron-specific Mecp2 KOs (43, 61, 63–65). In contrast, removal of MeCP2 from astrocytes or microglia results in mild behavioral phenotypes without affecting lifespan (66, 67). Thus, the function of MeCP2 in the glial cell types assayed does not appear to drive pathogenesis, though Mecp2 expression in astrocytes improves the breathing symptoms of mice lacking MeCP2 in all other cell types (66). Consistent with a primarily neuron-driven pathogenesis, Mecp2 expression only in postmitotic neurons normalized brain weight and activity (68) and extended lifespan beyond 8 months of age, despite incomplete Mecp2 expression (70%–90% of neurons, depending on region) (69). Taken together, these data strongly suggest that loss of MeCP2 function in neurons is the dominant cause of dysfunction in Rett syndrome.

Given the severity of the Mecp2-null mutant models, two main questions emerged: (a) When is MeCP2 required, and (b) is this damage reversible, given that neurons lacking MeCP2 do not die? To determine whether there was a critical window in which neurons required MeCP2 or whether MeCP2 was required constantly, Mecp2 expression was halted in adult mice (aged 2 months). Interestingly, after deletion of Mecp2 in the adult, half of the males die within 10 weeks, which is very similar to the timespan between birth and death seen in mice with germline deletion (70). Thus, MeCP2 is required throughout postmitotic neuronal life. To test the reversibility of Rett symptoms, Mecp2 expression was activated after the onset of neurological symptoms. This expression drastically decreased the severity of ataxia, hindlimb clasping, tremor, and irregular breathing and extended lifespan (54, 71). Therefore, a lack of MeCP2 does not result in irreversible neuronal damage, prompting hope for benefits from potential therapeutic treatments in patients with Rett syndrome.

Fortuitously, a mouse model generated in 2004 revealed that overexpression of MeCP2 also results in neuronal dysfunction, predicting human MDS (72). Specifically, mice that overexpress MeCP2 exhibit a progressive neurological disorder characterized by hypoactivity, social avoidance, anxiety, and seizures (Table 2 and refs. 68, 72, 73). Similar to the increased severity of patients with MECP2 triplication compared with those with MDS (74), the more MeCP2 expressed by mice, the worse their phenotype (72, 73). Strikingly, while neurons without MeCP2 exhibit a decrease in excitatory synapses and impaired long-term potentiation (LTP), neurons expressing twice the normal level of MeCP2 have an increased density of these synapses (75) and enhanced LTP (72). This apparent increase in excitability is correlated with the enhanced motor-learning ability of the mice (72). Thus, humans and mouse models of both loss and gain of MeCP2 function indicate that neurons are acutely sensitive to the dose of MeCP2, with too little or too much resulting in progressive neurological disorders.

From patient to protein: the molecular function of MeCP2

Methylation binding and beyond. Before mutations in MECP2 were known to form the genetic basis of Rett syndrome, MeCP2 had already been biochemically characterized as interacting with methylated cytosines, followed by a guanine via its methyl-CpG-binding domain (MBD) (Figure 1A and refs. 76, 77). Recently, it was discovered that the MBD of MeCP2 also binds methylated cytosines in the CH context (where H = A/T/C), with similar affinity both in vitro and in vivo (78–80). DNA methylation is a covalent modification of the genome that provides an additional layer of information beyond the sequence information; thus, it is considered an epigenetic mark. DNA methylation is critical to the processes of genomic imprinting, XCI, cellular differentiation, and the silencing of transposable elements (81, 82). Constitutive heterochromatin, such as pericentromeric repeats, is characterized by high levels of DNA methylation, is important for the structural integrity of the centromere, and is, as anticipated, highly enriched for MeCP2. However, DNA methylation is also distributed throughout the genome in intergenic regions, within enhancers, proximal to the transcription start site (TSS), and within gene bodies. The complexity of the modification, and hence a protein targeted by the modification, lies in its context dependency. For example, while methylation near the TSS is associated with long-term repression of a gene, methylation within gene bodies is not (83, 84). Furthermore, methylation in the adult brain is very unique among somatic tissues, given its high mCH content (~25% of mC) (78, 85). Strikingly, in both mice and humans, mCH emerges only as neurons mature (in 2- to 4-week-old mice), paralleling the increased abundance of MeCP2 (86, 87) and the global increase in synapse formation (85). Though we are arguably in the early stages of understanding the functional impact of mCH—as its relationship to expression varies in different cell types (85)—transcriptonal changes observed in KO and MECP2-overexpressing animals correlate more with mCH than with mCG (79, 80).

Given the presence of an MBD, early functional studies of MeCP2 operated under the assumption that MeCP2 was likely a transcriptional repressor. Indeed, in vitro transcriptional reporter assays using methylated templates indicated that MeCP2 was capable of repression via a region mapped to amino acids 207–310, named the transcriptional repression domain (TRD) (Figure 1A and ref. 88). However, in vivo transcriptional studies in many different brain regions comparing the KO transcriptome with that of mice overexpressing MECP2 indicated that the majority of misregulated genes are not upregulated in the KO mice, as is often observed upon mutation of a repressor (80, 89, 90). Although careful stud-

<table>
<thead>
<tr>
<th>MDS symptom</th>
<th>TG1 males</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor</td>
<td>Limited mobility</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Ataxic gait</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Stereotypies</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Spasticity</td>
<td>+</td>
</tr>
<tr>
<td>Cognitive and social abilities</td>
<td>Decreased cognition</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Speech loss</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Social avoidance</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
<td>+</td>
</tr>
<tr>
<td>Other</td>
<td>Recurrent infections</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Reduced lifespan</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Seizures</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Dysmorphic features</td>
<td>ND</td>
</tr>
</tbody>
</table>

+, observed in multiple studies; *, increased.
ies have not been performed to distinguish primary and secondary transcriptional effects, the fact that the majority of transcriptional changes are reciprocal between the KO and the MECP2-overexpressing mice suggests a nonrandom sensitivity of genes to MeCP2 function. Further, in contrast to derepression, a global decrease in transcription is observed in neurons derived from mouse and human embryonic stem cells lacking MeCP2 (46, 91).

It is important to consider the biochemical properties of MeCP2 when investigating the mechanistic details of its function. Circular dichroism spectroscopy indicates that the full-length protein is approximately 59% unstructured in solution (92). Trypsin digestion of MeCP2 supports deletion-mapping studies used to define the MBD and TRD, as these functional domains can be recovered intact at high trypsin concentrations, suggesting that they are structurally discrete (92). However, only the structure of the MBD has been successfully solved (93, 94). The isoelectric point of the full-length protein is highly basic (~10), suggesting the capacity for multiple DNA interaction regions. Indeed, many portions of MeCP2, aside from the MBD, have been shown to interact with DNA in a methylation-independent manner, including the TRD and the interdomain (ID) between the MBD and TRD (95). In fact, in 1992, with the initial cloning of MeCP2, the authors were struck by the abundance of short basic motifs in the protein, which were known at the time to facilitate DNA binding (76). However, it was not until recently that comparative computational analysis facilitated the mapping of three AT-hooks in MeCP2, which are specialized basic clusters that bind the minor groove of AT-rich DNA (Figure 1B and refs. 96). Further, comparing two patient mutations with and without AT-hook 2, G273X and R270X, respectively, established that AT-hook 2 contributes to MeCP2 DNA binding in vivo and in vitro (96). Importantly, this difference in DNA binding corresponded with a four-month longer median lifespan of G273X mice than that of R270X mice, consistent with patient outcomes (96).

Interestingly, MeCP2 exhibits homology to the high-mobility group AT-hook (HMGA) family of chromatin modulators, which contain two or three AT-hooks connected by a flexible linker (96). The specialized ability of HMGA proteins to nonenzymatically induce DNA bending via their AT-hooks suggests that these motifs within MeCP2 may contribute to transcriptional function in addition to binding (Figure 2A and ref. 97).

**MeCP2 in the chromatin context.** MeCP2 is broadly expressed throughout the body but is most abundant in mature neurons. In fact, it is estimated that there are an average of 16 million MeCP2 molecules in a neuronal nucleus compared with 32 million nucleosomes (86). This astonishing abundance may be critical to understanding the role of MeCP2 in the nucleus and the singular failure of neurons upon its loss. By comparison, MeCP2 protein levels are approximately 30 times lower in liver nuclei and seven times lower in glia (86). Additionally, MeCP2 protein levels are temporally regulated, such that they increase to a plateau during the time of neuronal maturation (49, 86, 87). Given the near-nucleosome abundance of MeCP2 in neuronal nuclei and the ability of multiple regions of the protein to interact with DNA, it was not surprising that genome-wide ChIP analysis showed broad localization of MeCP2 throughout the genome (80, 86, 98, 99). Although MeCP2 enrichment tracks with DNA methylation (mCG and mCH), the enrichment of MeCP2 at the highly methylated major satellite repeats, for example, is only 2–3 times higher than that of the genomic average (80, 86). Although biochemically consistent, the broad chromatin localization of MeCP2 challenged many simple mechanistic models. Could a site-specific repressor be at near-nucleosome levels and broadly distributed across the genome? Recent work investigating the common R306C mutation (found in ~5% of Rett syndrome patients), which falls at the edge of
the TRD, found that this mutation ablates the interaction of MeCP2 with the nuclear receptor corepressor/SMRT (NCoR/SMRT) complex in vivo and in vitro (Figure 2B and refs. 100, 101). It remains to be seen whether NCoR/SMRT and MeCP2 colocalize at genes that are misregulated in mutants lacking either protein and what the functional overlap of misexpression is in the respective mutants. While this is an exciting molecular finding, patients with the R306C mutation have delayed onset of symptoms and decreased disease severity compared with patients who have MBD mutations or earlier truncations (Figure 1C and refs. 102–104). These findings are consistent with those in mouse models, suggesting that the NCoR interaction cannot fully explain the function of MeCP2.

The nuclear abundance and broad distribution of MeCP2 raise the possibility that it plays a structural role to affect chromatin. The fundamental structural unit of chromatin is the nucleosome, a histone octamer wrapped in 1.65 turns of DNA (red). The DNA between nucleosomes is called linker DNA (yellow) and MeCP2 share a common nucleosomal binding site, the linker DNA entry/exit position. MeCP2 is able to compete off histone H1 in vitro, like HMGA proteins, and neurons lacking MeCP2 display increased H1. H1 plays a critical role in establishing higher-order chromatin, suggesting that antagonism by MeCP2 affects chromatin architecture. (B) MeCP2 may alter transcription by recruiting effector proteins. MeCP2 is able to repress methylated reporters in vitro when its TRD is intact. Thus, the TRD (within the flexible, basic C-terminus [purple]) may function as a bridge between MBD (blue) targeting and transcriptional effectors. Recently, it was discovered that Rett patient mutation R306C (edge of the TRD) disrupts interaction of MeCP2 with the NCoR/SMRT corepressor complex.

Figure 2. Functional modes of MeCP2. (A) One critical activity of MeCP2 is the binding of methylated cytosines through its MBD (blue). Once it binds DNA, MeCP2 may function by altering the chromatin structure. Left: AT-hooks are able to change the conformation of DNA. The presence of three AT-hooks in MeCP2 suggests that MeCP2 may be able to bend DNA like the HMGA proteins with which MeCP2 exhibits homology. In this scenario, the primary targeting of MeCP2 via the MBD would then allow the flexible C-terminus of the protein (purple) to engage proximal DNA via its positively charged AT-hooks. Right: The fundamental unit of chromatin is the nucleosome, a histone octamer wrapped in 1.65 turns of DNA (red). The DNA between nucleosomes is called linker DNA. Linker histone H1 (yellow) and MeCP2 share a common nucleosomal binding site, the linker DNA entry/exit position. MeCP2 is able to compete off histone H1 in vitro, like HMGA proteins, and neurons lacking MeCP2 display increased H1. H1 plays a critical role in establishing higher-order chromatin, suggesting that antagonism by MeCP2 affects chromatin architecture. (B) MeCP2 may alter transcription by recruiting effector proteins. MeCP2 is able to repress methylated reporters in vitro when its TRD is intact. Thus, the TRD (within the flexible, basic C-terminus [purple]) may function as a bridge between MBD (blue) targeting and transcriptional effectors. Recently, it was discovered that Rett patient mutation R306C (edge of the TRD) disrupts interaction of MeCP2 with the NCoR/SMRT corepressor complex.

Finally, it is essential to note that neurons form a specialized class of postmitotic cells that constantly undergo bursts of activity in response to their environment. Although MeCP2 is subject to many activity-induced posttranslational modifications (117, 118), the functional role of MeCP2 upon neuronal activity is poorly understood in vivo. Knockin mice expressing a mutant form of MeCP2
that cannot undergo activity-dependent phosphorylation at T308 exhibit microcephaly, a phenotype associated with hypomorphic alleles (118). Interestingly, cultured cortical neurons from these mice display decreased activity-induced expression, suggesting that MeCP2 may influence this process. Further, recent work using the odorant-evoked induction paradigm demonstrated defective transcriptional induction in olfactory sensory neurons of KO animals (119). However, much more research is needed to determine the molecular function of MeCP2 during the activity cycles of neurons and how a lack of this function might lead to disease.

Therapeutic promise: getting back to the clinic

Amelioration of the symptoms of sufferers of MECP2 disorders does not require absolute mechanistic knowledge of the molecular function of MeCP2. The reversibility of the phenotypes in the Rett mouse model established the potential benefit of therapeutic intervention in patients. Thus far, however, no interventions have fully rescued KO animals. While modest improvements have been observed, as described below, it is important to be cautiously optimistic while the transition is made to human patients, as the path to clinical translation is notoriously fraught with challenges. Fortunately, preclinical trials in patients with MECP2 disorders are strengthened by the face validity of both the Rett and MDS mouse models (see Tables 1 and 2) as well as by the continued focus within the community on best practices of blinding, randomization, and replication (120).

Initial attempts to rescue Rett mouse models focused on reversing the putative damage caused by the transcriptional changes observed in the KO animals. KO animals exhibit decreased RNA and protein levels of brain-derived neurotrophic factor (BDNF) (89, 121, 122). Given the importance of BDNF as a neuronal growth factor, attempts have been made to normalize the levels of BDNF in KO animals genetically and pharmacologically. Overexpression of BDNF extends the median lifespan of KO animals by 3 weeks (121). Further, treatment with the ampakine CX546 increased BDNF in KO animals and restored respiratory frequency and respiratory minute volume to WT levels (123). Additionally, increasing BDNF in KO animals via administration of fingolimod resulted in total rescue of motor dysfunction, as measured by the ability to stay on the rotating rod, and a 3- to 4-week extension of median lifespan (124). Importantly, the BDNF V66M polymorphism in patients with Rett syndrome appears to modulate the severity of symptoms in humans (125). Thus, two small clinical trials are currently underway to explore the effects of FDA-approved copaxone (glatiramer acetate), which has been shown to increase the number of BDNF-expressing cells in KO animals (126), on outcomes in patients with Rett syndrome.

Given the low penetrance of BDNF across the blood-brain barrier, other studies have focused on similar growth factors that might be more clinically tractable. Specifically, administration of the tripeptide insulin-like growth factor 1 (IGF1) to KO animals resulted in an extension of lifespan similar to that observed with BDNF overexpression and partially rescues locomotor activity, breathing variability, spine density, and synaptic amplitude (127). Further, IGF1 treatment increased the number of glutamatergic synapses in neurons derived from induced pluripotent stem cells (iPSCs) from Rett syndrome patients (45). Although delivery of full-length human IGF1 (mecasermin) to KO animals resulted in a less robust phenotypic rescue than did the tripeptide formulation (128), a phase I clinical trial (NCT identifier 01253317) in Rett patients indicated good drug tolerance (129). The efficacy of this treatment will be clearer upon completion of the current phase II trials (NCT identifier 01777542).

Additional potential therapies have focused on neurotransmitter deficiencies. Given the decrease in dopamine metabolites in patients with Rett and in mouse models (55, 61, 130) and the decreased dopaminergic activity in the substantia nigra observed in KO animals (56), the impact of levodopa (L-DOPA) therapy on KO animals was assessed. The locomotor activity of treated animals, as measured by distance traveled in the open-field assay, doubled (56). KO animals also exhibit decreased GABA levels in some areas of their brains (57, 131), and administration of the GABA reuptake inhibitor NO-711 resulted in a four-fold decrease in apnea frequency (132). Serotonin receptor agonists have also been successful in ameliorating the breathing abnormalities of KO animals (132, 133).

Strategies for the future

Future therapeutic strategies being explored for patients with Rett syndrome include gene therapy and reactivation of the X chromosome carrying the WT MECP2 allele. Neonatal bilateral intracranial injection of AAV9 containing MECP2 cDNA into KO animals resulted in 7% to 41% cellular transduction, depending on brain region, and extended median lifespan by 7 weeks compared with treatment with a virus encoding GFP (134). AAV9 was used, as it crosses the blood-brain barrier (135, 136); however, in the same study, tail-vein injection of the virus into 4- to 5-week old mice resulted in only 2% to 4% transduction. Strikingly, this minimal increase in MeCP2 levels appeared to extend the median lifespan by 5 weeks compared with that of un.injected animals (134). In a similar proof-of-concept study, AAV9 encoding Mecp2 was injected into the tails of 4- to 6-week-old KO animals, achieving transduction of 7% to 26% of cells in the brain regions assayed (137). Although each group only contained 5 animals, KO animals that received viral Mecp2 had a median lifespan that was approximately 15 weeks longer than that of mice injected with the viral control. Further, to better model gene therapy in patients with Rett syndrome, symptomatic heterozygous female mice were injected and showed continuous improvement in phenotypic severity scores, apnea frequency, and motor activity over a 20-week monitoring period (137). Of note, both of the above studies used viral DNA encoding the e1 isoform of MECP2/Mecp2, which does not include exon 2 and is more highly expressed in the brain than the e2 isoform containing exon 2 (138). Thus, while in its early stages of preclinical development, gene therapy may be an emergent therapeutic as long as the levels of MeCP2 delivered do not exceed the threshold for overexpression phenotypes. Additionally, although current analysis of patient mutations in mouse models (RI11G, R270X, G273X, and R306C) indicates that these mutations are fully complemented by the WT allele, it is formally possible that some mutations in patients might be dominant-negative and require inhibition (96, 101).

One major concern with all therapies that target MeCP2 levels — whether delivering much-needed WT protein to Rett patients or decreasing the level of MeCP2 in sufferers of MDS — is maintaining the fine line of subclinical alterations in MeCP2 dosage. In a similar vein, increasing the dosage of more than a thousand X-linked genes in females with Rett syndrome by reactivating
an inactive X chromosome that may contain the repressed WT allele might seem dangerous, given the evolutionary drive to keep a single dose of most X-linked genes. However, recent work has uncovered a mouse mutation that results in biallelic expression of MeCP2, without increasing expression of the majority of X-linked genes (139). Thus, this work opens the door for possible selective dual expression of MECP2 in patients with Rett syndrome, ensuring that each neuron expresses the WT allele. While this work represents a large leap forward, further work is necessary to determine whether biallelic expression of even a few X-linked genes other than MECP2 is deleterious.

Although mouse models of MDS have not formally been tested for reversibility, the progressive nature of the disorder, the absence of neuronal death, and the reversibility of MeCP2 loss-of-function mutations suggest that this disorder might be ameliorated by decreasing MeCP2 levels. If MDS mouse models are rescued by halving the amount of MeCP2, many avenues of intervention might be fruitful, such as inhibition of proteins that stabilize or activate MeCP2, targeted destabilization of the MECP2 transcript, or inhibition of critical downstream pathways that are overactivated in MDS. Importantly, mice with a 50% decrease in MeCP2 levels exhibit measurable motor and behavioral dysfunction (140). Thus, treatments for MDS that decrease MeCP2 levels will require patient-specific dosing to ensure MeCP2 levels do not drop below the threshold that induces Rett-like symptoms.

Outlook

In the past 15 years, the development of mouse models of both Rett syndrome and MDS have enabled detailed behavioral, neurocomputational, cellular, and molecular insights into these disorders that would not have otherwise been possible. Further, these robust models have revealed multiple potential therapeutic entry points, many of which are currently being explored in preclinical and clinical trials. Ongoing basic research into the molecular function of MeCP2 and the impact of its loss or gain will no doubt yield greater depth to our understanding of these disorders and unveil even more potential therapeutics. Thus, we are well into the promising stage of returning to the clinic with the knowledge we have gleaned at the bench.

Acknowledgments

The authors wish to dedicate this Review to the memory of Professor Bengt Hagberg (1923–2015), whose stellar clinical work inspired Huda Zoghbi to recognize the syndrome and pursue its etiology. We are very grateful to the families of individuals with Rett syndrome and MDS for their participation in our studies. Work by the authors has been supported by grants from the National Institute of Neurological Disorders and Stroke (NS057819), the Rett Syndrome Research Trust, and the International Rett Syndrome Foundation. L.M. Lombardi and H.Y. Zoghbi are also funded by the Howard Hughes Medical Institute. We apologize to the authors whose many fine studies on MeCP2 function we were unable to discuss due to space limitations and to the clinical focus of this work.

Address correspondence to: Huda Yahya Zoghbi, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA. Phone: 713.798.6523; E-mail: hzoghbi@bcm.edu.


